---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-21-024551"
form_type: "8-K"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2021-12-06T23:59:59+00:00"
generated_at: "2026-06-28T03:30:23.350724+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Avalo Therapeutics appoints Dr. June Almenoff and Mitchell Chan as independent directors

## Summary
- Dr. June Almenoff appointed effective Nov 10, 2021; replaces Dr. Suzanne Bruhn.
- Mitchell Chan appointed effective Dec 1, 2021; replaces Philip Gutry per Armistice Capital agreement.
- Dr. Almenoff is CMO at RedHill Biopharma, ex-CMO of Furiex (acquired by Actavis), and former GSK executive.
- Mr. Chan ex-CFO of Viela Bio (led $750M+ capital raises and $3.1B Horizon acquisition), prior roles at AstraZeneca and Genentech-Roche.
- Chan will chair Audit Committee and serve on Compensation Committee; both are independent directors.

## SEC filing metadata
- accession: 0001628280-21-024551
- form_type: 8-K
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2021-12-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000162828021024551/0001628280-21-024551-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000162828021024551/avtx-20211201.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-21-024551
- JSON: https://secwatch.observer/filing/0001628280-21-024551.json
- Plain text: https://secwatch.observer/filing/0001628280-21-024551.txt

## Key facts
- Executive change
  Philip Gutry resigned as Director at Avalo Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: As previously reported, pursuant to the Agreement, Mr. Philip Gutry’s resignation from the Board became effective on the date of Mr. Chan’s appointment to the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534120/000162828021024551/0001628280-21-024551-index.htm
- Executive change
  Mitchell Chan was appointed as Director at Avalo Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: On December 1, 2021, the board of directors (the “ Board ”) of Avalo Therapeutics, Inc. (the “ Company ”) appointed Mitchell Chan, to the Board, effective immediately, pursuant to the terms of that certain Cooperation Agreement, dated as of November 4, 2021, with Armistice Capital, LLC (“ Agreement ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534120/000162828021024551/0001628280-21-024551-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.